专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

EP1740617B1 METHOD FOR THE TREATMENT OF T CELL MEDIATED CONDITIONS BY DEPLETION OF ICOS-POSITIVE CELLS IN VIVO 失效
标题翻译：方法与T-细胞疾病杂志CONNECTION STAND BY消除体内ICOS阳性细胞移植治疗
公开(公告)号：EP1740617B1
公开(公告)日：2013-10-16
申请号：EP05737106.4
申请日：2005-04-22
申请人： BUNDESREPUBLIK DEUTSCHLAND letztvertreten durch das Robert Koch-Institut vertreten durch seinen Präsidenten
发明人： KROCZEK, Richard
IPC分类号： C07K16/28 , A61K39/395 , C07K14/705 , A61P37/06
CPC分类号： C07K16/28 , A61K38/00 , A61K2039/505 , C07K14/70521 , C07K16/2818 , C07K2317/73 , C07K2317/74 , C07K2317/77 , G01N33/505 , G01N2800/24

2. 发明公开

EP2062592A1 System for delivery into a XCR1 positive cell and uses thereof 审中-公开
标题翻译：系统zur Abgabe在eine阳性XCR1-Zelle和Verwendungendafür
公开(公告)号：EP2062592A1
公开(公告)日：2009-05-27
申请号：EP07022471.2
申请日：2007-11-20
申请人： BUNDESREPUBLIK DEUTSCHLAND letztvertreten durch das Robert Koch-Institut vertreten durch seinen Präsidenten
发明人： Kroczek, Richard
IPC分类号： A61K38/19 , A61K39/395 , A61K47/48 , A61P37/00 , A61P35/00
CPC分类号： C07K16/2866 , A61K38/195 , A61K39/385 , A61K47/646 , A61K47/6849 , A61K2039/577 , A61K2039/6056 , Y02A50/41 , Y02A50/412
摘要： The present invention relates to a delivery system suitable for delivering a substance into a XCR1 positive professional antigen-presenting cell, one or more nucleic acids coding for the same, a vector comprising the nucleic acid(s), a medicament comprising the delivery system or the one or more nucleic acid(s) and an adjuvant comprising XCL1 or a functionally active fragment thereof.
摘要翻译：本发明涉及一种适合于将物质递送到XCR1阳性专业抗原呈递细胞中的递送系统，一种或多种编码该核酸的核酸，包含该核酸的载体，包含递送系统的药物或一种或多种核酸和包含XCL1或其功能活性片段的佐剂。

3. 发明公开

EP1757304A1 Pharmaceutical composition and its use for the prophylactic or therapeutic treatment of retroviral diseases 审中-公开
标题翻译：一种药物组合物和其用于治疗逆转录病毒疾病的预防性和治疗性治疗中使用
公开(公告)号：EP1757304A1
公开(公告)日：2007-02-28
申请号：EP05090247.7
申请日：2005-08-26
申请人： Bundesrepublik Deutschland vertreten durch das Bundesminsterium für Gesundheit, dieses vertr. durch das Robert-Koch-Institut
发明人： Denner, Joachim , Langhammer, Stefan , Fiebig, Uwe , Kurth, Reinhard
IPC分类号： A61K39/21 , A61K38/02 , A61K39/42 , A61P31/18
CPC分类号： C07K16/1036 , A61K38/162 , A61K39/12 , A61K39/21 , A61K2039/53 , A61K2039/55566 , A61K2039/55577 , C07K14/005 , C07K2317/34 , C07K2317/76 , C12N2740/13022 , C12N2740/13034 , C12N2740/16222
摘要： The invention relates to a pharmaceutical combined composition comprising as active ingredients an effective amount of the retroviral transmembrane envelope protein p15E, gp41 or gp36, and an effective amount of a retroviral surface envelope protein, whereby said proteins are contained as single molecules, for inducing neutralizing antibodies which are directed against retroviral infections. The invention also relates to a method for inducing an antibody response and a method for passive immunization of a mammal by using neutralizing antibodies which are generated with said pharmaceutical composition.
摘要翻译：本发明涉及的药物组合的组合物，其包含如在有效量的反转录病毒跨膜包膜蛋白p15E的，gp41的或gp36的，并且在有效量的逆转录病毒表面包膜蛋白，由此所述蛋白质包含作为单个分子的活性成分，用于诱导中和其中抗体针对逆转录病毒感染。因此本发明涉及一种用于在抗体应答和对哺乳动物的被动免疫，通过使用中和抗体其与所述药物组合物产生的方法诱导的方法。

4. 发明公开

EP1754715A1 Impfstoff auf Basis virusneutralisierender Antikörper 审中-公开
标题翻译：防毒基因病毒中和抗体
公开(公告)号：EP1754715A1
公开(公告)日：2007-02-21
申请号：EP05090240.2
申请日：2005-08-19
申请人： Bundesrepublik Deutschland vertreten durch das Bundesminsterium für Gesundheit, dieses vertr. durch das Robert-Koch-Institut
发明人： Denner, Joachim, Dr. , Langhammer, Stefan , Fiebig, Uwe , Kurth, Reinhard, Prof. Dr.
IPC分类号： C07K14/16 , C07K16/10 , C07K19/00 , C12N15/48 , C12N15/62 , A61K39/21 , G01N33/68
CPC分类号： C07K16/1063 , C07K14/005 , C07K2317/92 , C12N2740/16122
摘要： Die Erfindung betrifft immunogene Konstrukte und ein pharmazeutisches Mittel zur Induktion von humoralen neutralisierenden Immunantworten gegen Retrovirusinfektionen, vorrangig HIV. Die Erfindung betrifft weiterhin ein Verfahren zur Induktion einer Antikörperantwort und ein Verfahren zur passiven Immunisierung eines Organismus unter Verwendung neutralisierender Antikörper, die mit den genannten immunogenen Konstrukten gewonnen wurden.
摘要翻译：包含两个逆转录病毒跨膜包膜蛋白（EP）的氨基酸（aa）序列的免疫原性构建体（A）是新的。包含两个逆转录病毒跨膜包膜蛋白（EP）的氨基酸（aa）序列的免疫原性构建体（A）是新的。它包括第一逆转录病毒的EP（或片段），其在融合域（FD）和N末端螺旋区域（NHR）之间的区域中包括第一aa序列（1），并且在区域在膜通道（MP）和C末端螺旋区域（CHR）之间的第二个aa序列（2）。（2）来自第二逆转录病毒的EP，并且替换第一逆转录病毒的EP的同源的第二和/或第三结构的序列。序列（1）和（2）彼此反平行排列。或者或另外，（A）包括编码（1）和（2）的DNA。包括以下独立权利要求：（1）用（A）免疫制备的中和抗体（Ab）; （2）用于检测特异性使用（A）的逆转录病毒的抗体的免疫学方法; （3）检测使用Ab的逆转录病毒抗原的免疫学方法; （4）通过施用（A）诱导抗体应答的方法; 和（5）被动免疫方法，包括施用Ab。活动：抗艾滋病毒杀病毒。没有给出这些活动的测试细节。动作机制：疫苗; 被动免疫。

5. 发明公开

EP1582591A3 Sirna and their use for knock down expression of porcine endogenous retrovirus 审中-公开
标题翻译： siRNA和它们的使用击倒内源性逆转录病毒的表达，猪
公开(公告)号：EP1582591A3
公开(公告)日：2005-12-21
申请号：EP05090046.3
申请日：2005-02-25
申请人： Bundesrepublik Deutschland vertreten durch das Bundesminsterium für Gesundheit, dieses vertr. durch das Robert-Koch-Institut
发明人： Karlas, Alexander , Denner, Joachim, Dr. , Kurth, Reinhardt, Prof.Dr.
IPC分类号： C12N15/11 , A61K31/713 , C12N5/10 , A01K67/027
CPC分类号： C12N15/1132 , A61K38/00 , C12N2310/111 , C12N2310/14
摘要： Transplantation of porcine xenografts into human recipients is a realistic option to overcome the growing worldwide shortage of suitable allogeneic organs. However, there remains the risk of infection by porcine endogenous retroviruses (PERVs) that cannot be eliminated like that by other microorganisms by breeding pigs under specified pathogen free conditions. To reduce the release of PERVs by porcine transplants a new approach, RNA interference (RNAi), was applied. Here we show significant reduction of PERV expression by synthetic short interfering RNAs (siRNAs) corresponding to different parts of the viral genes gag, pol and env . The most inhibitory sequences were selected and expressed as short hairpin RNAs (shRNAs) by a polymerase III vector system leading to persistent suppression of PERV replication. Cells or organs from transgenic pigs producing such shRNAs should increase the safety of xenotransplantation.

6. 发明公开

EP3119422A2 A MEDICAMENT FOR USE IN A METHOD OF INDUCING OR EXTENDING A CELLULAR CYTOTOXIC IMMUNE RESPONSE 审中-公开
标题翻译：药物用在方法诱导或细胞免疫反应的细胞毒性延长
公开(公告)号：EP3119422A2
公开(公告)日：2017-01-25
申请号：EP15711125.3
申请日：2015-03-17
申请人： BUNDESREPUBLIK DEUTSCHLAND letztvertreten durch das Robert Koch-Institut vertreten durch seinen Präsidenten
发明人： KROCZEK, Richard
IPC分类号： A61K39/00
CPC分类号： A61K39/0011 , A61K2039/5154 , A61K2039/5158 , A61K2039/545 , A61K2039/55533 , A61K2039/55561 , A61K2039/572
摘要： The present invention relates to a medicament for use in a method of extending a cellular cytotoxic immune response against an antigen-comprising protein, the method comprising the step of: i) administering to a patient having T cells activated against an antigen a peptide-loaded major histocompatibility complex class I (MHC-I) presenting cell and an adjuvant which supports a Th-1-mediated response, wherein the peptide is derived from the antigen-comprising protein, thereby re-activating the activated T cell, wherein the peptide-loaded major histocompatibility complex class I (MHC-I) presenting cell of step i) is administered in a time frame of from 0 h to 14 days after the T cells were activated against an antigen.
摘要翻译：本发明涉及一种用于使用的药剂在诱导细胞毒性免疫应答的方法，该方法包括以下步骤：i给予患者的递送系统，包括（a）的分子结合到受体的表面上）树突细胞，（b）关于在的分子的结合结合至（a）和（c）第一佐剂，worin的分子抗原包含蛋白质（a）至受体，（b）的被内在化的蛋白质和在树突状细胞加工并在蛋白质包含在抗原呈现在树突状细胞的表面上，从而激活在患者的T细胞; 和ii）向患者施用选自重新活化剂选自（D）复合的白细胞介素2（IL-2CX），（E）的肽负载主要组织相容性复合物I类（MHC-I）呈递细胞和第二辅助剂，和（f）的（d）中的组合和（e），worin将肽从抗原包括蛋白质衍生作为在步骤i）中所定义，从而重新激活在步骤激活T细胞i）中，worin再活化剂对步骤ii）的在的时帧的步骤i）中的递送系统的给药之后给予从0小时至14天。

7. 发明公开

EP1740617A1 METHOD FOR THE TREATMENT OF T CELL MEDIATED CONDITIONS BY DEPLETION OF ICOS-POSITIVE CELLS IN VIVO 失效
标题翻译：方法与T-细胞疾病杂志CONNECTION STAND BY消除体内ICOS阳性细胞移植治疗
公开(公告)号：EP1740617A1
公开(公告)日：2007-01-10
申请号：EP05737106.4
申请日：2005-04-22
申请人： BUNDESREPUBLIK DEUTSCHLAND letztvertreten durch das Robert Koch-Institut vertreten durch seinen Präsidenten
发明人： KROCZEK, Richard
IPC分类号： C07K16/28 , A61K39/395 , C07K14/705 , A61P37/06
CPC分类号： C07K16/28 , A61K38/00 , A61K2039/505 , C07K14/70521 , C07K16/2818 , C07K2317/73 , C07K2317/74 , C07K2317/77 , G01N33/505 , G01N2800/24
摘要： The present invention relates generally to binding agents useful in the selective depletion of T cells in vivo. More specifically, the invention relates to ICOS-binding agents which once bound to ICOS expressed on the surface of cells, in particular ICOS-bearing activated T cells, result in the in vivo depletion of cells to which they are bound. Methods of treating T cell related diseases using said ICOS-binding agents, and pharmaceutical compositions comprising said ICOS-binding agents, a method of identifying an ICOS-binding agent, and monoclonal anti-ICOS antibodies capable of eliminating cells in vivo which express ICOS on their surface are also provided.

8. 发明公开

EP3160495A1 A MEDICAMENT FOR USE IN A METHOD OF INDUCING OR EXTENDING A CELLULAR CYTOTOXIC IMMUNE RESPONSE 有权
标题翻译：药物用在方法诱导或细胞免疫反应的细胞毒性延长
公开(公告)号：EP3160495A1
公开(公告)日：2017-05-03
申请号：EP15710769.9
申请日：2015-03-17
申请人： BUNDESREPUBLIK DEUTSCHLAND letztvertreten durch das Robert Koch-Institut vertreten durch seinen Präsidenten
发明人： KROCZEK, Richard
IPC分类号： A61K39/00
CPC分类号： A61K39/0011 , A61K2039/5154 , A61K2039/5158 , A61K2039/545 , A61K2039/55533 , A61K2039/55561 , A61K2039/572
摘要： The present invention relates to a medicament for use in a method of inducing a cellular cytotoxic immune response, the method comprising the steps of: i) administering to a patient a delivery system comprising (a) a molecule binding to a receptor on the surface of a dendritic cell, (b) an antigen-comprising protein bound to molecule of (a) and (c) a first adjuvant, wherein upon binding of the molecule of (a) to the receptor, the protein of (b) is internalized and processed in the dendritic cell and the antigen comprised in the protein is presented on the surface of the dendritic cell, thereby activating a T cell in the patient; and ii) administering to the patient a re-activator selected from the group consisting of (d) complexed interleukin 2 (IL-2cx), (e) a peptide-loaded major histocompatibility complex class I (MHC-I) presenting cell and a second adjuvant, and (f) a combination of (d) and (e), wherein the peptide is derived from the antigen-comprising protein as defined in step i), thereby reactivating the T cell activated in step i), wherein the re-activator of step ii) is administered in a time frame of from 0 h to 14 days after the administration of the delivery system of step i).
摘要翻译：本发明涉及一种用于使用的药剂在诱导细胞毒性免疫应答的方法，该方法包括以下步骤：i给予患者的递送系统，包括（a）的分子结合到受体的表面上）树突细胞，（b）关于在的分子的结合结合至（a）和（c）第一佐剂，worin的分子抗原包含蛋白质（a）至受体，（b）的被内在化的蛋白质和在树突状细胞加工并在蛋白质包含在抗原呈现在树突状细胞的表面上，从而激活在患者的T细胞; 和ii）向患者施用选自重新活化剂选自（D）复合的白细胞介素2（IL-2CX），（E）的肽负载主要组织相容性复合物I类（MHC-I）呈递细胞和第二辅助剂，和（f）的（d）中的组合和（e），worin将肽从抗原包括蛋白质衍生作为在步骤i）中所定义，从而重新激活在步骤激活T细胞i）中，worin再活化剂对步骤ii）的在的时帧的步骤i）中的递送系统的给药之后给予从0小时至14天。

9. 发明授权

EP1181552B1 VERFAHREN ZUR DIAGNOSE TSE-INDUZIERTER VERÄNDERUNGEN IN GEWEBEN MITTELS INFRAROTSPEKTROSKOPIE 有权
标题翻译：用于组织诊断TSE后变化方法是指红外光谱法的
公开(公告)号：EP1181552B1
公开(公告)日：2003-04-09
申请号：EP00941900.3
申请日：2000-05-03
申请人： Robert-Koch-Institut
发明人： NAUMANN, Dieter , KNEIPP, Janina , BALDAUF, Elizabeth , LASCH, Peter , BEEKES, Michael
IPC分类号： G01N33/487 , G01N21/35
CPC分类号： G01N21/359 , G01N21/35 , G01N2021/3196 , Y10S436/811
摘要： The aim of the invention is to quickly diagnose TSE-induced changes in animal and human tissues by measuring infrared spectra of these tissues. Either thin slices of tissue, pieces of tissue or tissue homgenizates serve as tissue samples. The measurements of the infrared spectra are carried out in a known experimental device that is used in infrared spectroscopy (e.g. in transmission, attenuated total reflection, direct or diffuse reflection). The detection of the pathological changes induced by TSE is carried out by comparing the infrared spectra of the sample to be examined with a reference data bank consisting of infrared spectra that were obtained from healthy material or from pathologically changed tissue samples. The conformation of the spectra of unknown samples with the reference data bank is preferably carried out using pattern recognition techniques (e.g. multivariate statistical models, artificial neuronal networks, genetic algorithms).

10. 发明公开

EP3902560A1 A PEPTIDE-MHC-I-ANTIBODY FUSION PROTEIN FOR THERAPEUTIC USE IN A PATIENT WITH AMPLIFIED IMMUNE RESPONSE 审中-公开
公开(公告)号：EP3902560A1
公开(公告)日：2021-11-03
申请号：EP19821090.8
申请日：2019-12-18
申请人： F. Hoffmann-La Roche AG , Robert Koch-Institut
发明人： KNOETGEN, Hendrik , FISCHER, Cornelia , KROCZEK, Richard
IPC分类号： A61K39/12 , A61K39/395 , C07K14/74 , C07K16/28 , C07K14/005 , C07K16/40

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式